BioMarin Pharmaceutical Inc. (BMRN)
| Previous Close | 91.51 |
| Open | 92.58 |
| Bid | 91.44 x 100 |
| Ask | 91.56 x 100 |
| Day's Range | 90.16 - 91.68 |
| 52 Week Range | 76.02 - 100.31 |
| Volume | |
| Avg. Volume | 1,390,743 |
| Market Cap | 17.378B |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | 105.25 |
| EPS (TTM) | 0.87 |
| Earnings Date | Apr 24, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 109.70 |
GuruFocus.comInsider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...
Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and commercializing innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases, has reported an insider sell according to a recent SEC filing.
PR NewswireBioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24, at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update.
GuruFocus.comInsider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ...
George Davis, the Executive Vice President and Chief Legal Officer of Biomarin Pharmaceutical Inc (NASDAQ:BMRN), has sold 24,602 shares of the company on March 28, 2024, according to a recent SEC filing.
